Skip to content

Bread Daily Intake Enriched With Mix Fibers in Metabolic Subjects: Intestinal Microbiota and Metabolic Profile Impact

Study of the Impact of Daily Bread Consumption Enriched With a Fibre Mix on Intestinal Microbiota and Metabolic Profile in Subjects at Metabolic Risk

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03875898
Acronym
Breath
Enrollment
40
Registered
2019-03-15
Start date
2017-06-08
Completion date
2018-11-26
Last updated
2019-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Obesity, Metabolically

Brief summary

The level of fibre consumption in France is lower than the national and international recommendations (mean 18.8 g/d for men, 16.4 g/d for women (INCA 2007 Study) instead of 30g/d recommended). Fibre have beneficial effects on health and interact with the intestinal microbiota diversity: a diet fortified with different structure fibres increase of 25 % the dysbiotic intestinal microbiota in obese patient (Cotillard et al, Dietary intervention impact on gut microbial gene richness. Nature, August 2013). The study aim is to evaluate the impact of daily consumption of bread (150 g ) enriched with a mixture of fibres of different structure (15g) during two months on the intestinal microbiota composition in metabolic risk subjects (abdominal overweight or obese) and also, to assess the correlation between the microbiota change and their metabolic profile improvement.It is a mono centric study with a centre in LYON (Centre de Recherche en Nutrition Humaine Rhône-Alpes)

Interventions

OTHER150 g bread fortified (15 g mix fibre)

Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.

OTHER150 g unfortified bread

Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks

Sponsors

Bridor
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Body Mass Index of 25 to 35 kg/m2 * Waist circumference greater than 80 cm for women and than 96 cm for men * Low level of fibre intake (\<20 g /d) and low level of fibre nature diversity * Daily bread consumption

Exclusion criteria

* Bread products allergy or intolerance * Digestive surgery history except appendicectomy * Metabolic or gastrointestinal disease history * Medication that could interfere with glucose and lipid metabolism or intestinal microbiota (for example, no antibiotics within the 3 months before the study) * Smokers (5 cig/d or more)

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline Intestinal microbiota composition at eight weeksbaseline and eight weeksintestinal microbiota composition will be measured by metagenomic analysis before all interventions, and before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)

Secondary

MeasureTime frameDescription
Change from baseline fasting and post prandial plasma glucose at eight weeksbaseline and eight weeksPlasma glucose will be measured in the fasting state and in the post-meal period over 7 hours before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from baseline fasting and post prandial plasma Insulin at eight weeksbaseline and eight weeksPlasma insulin will be measured in the fasting state and in the post-meal period over 7 hours before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from baseline fasting and post prandial plasma triglycerides at eight weeksbaseline and eight weeksPlasma triglycerides will be measured in the fasting state and in the post-meal period over 7 hours before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from baseline fasting and post prandial plasma non-esterified fatty acids at eight weeksbaseline and eight weeksPlasma non-esterified fatty acids will be measured in the fasting state and in the post-meal period over 7 hours before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from baseline fasting plasma lipids (cholesterol total, cholesterol HDL and LDL) at eight weeksbaseline and eight weeksFasting plasma lipids will be measured before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from baseline C-Reactive Protein at eight weeksbaseline and eight weeksCRPus will be measured before and after each eight weeks, consumption sequences (fiber-fortified bread vs unfortified)
Change from baseline Acetylated ghrelin at eight weeksbaseline and eight weeksAcylated ghrelin will be measured in the fasting state and postprandial period (at 0 and 240 min) before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from baseline MDA (Malon Di Aldehyde) at eight weeksbaseline and eight weeksMDA will be measured before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from baseline Body composition at eight weeksbaseline and eight weeksBody composition will be measured with bio-impedancemetry before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified)
Change from Baseline Resting Energy Expenditure at eight weeksbaseline and eight weeksResting Energy Expenditure will be measured with indirect calorimetry before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified).
Change from Baseline substrate oxydation at eight weeksbaseline and eight weeksSubstrate oxydation (in the postprandial period over 7 hours) will be measured with indirect calorimetry before and after each eight weeks consumption sequence (fibre-fortified bread vs unfortified).
Change from baseline fibre intake at eight weeksbaseline and eight weeksThe volunteers will complete a dietary survey of three days and fibre questionnaire
Change from baseline Gastrointestinal tolerance symptoms at eight weeks.baseline and eight weeksSubjective ratings of bloating, nausea, vomiting, abdominal cramping and flatulence will be measured using visual analogue scale (VAS) score (on a 90mm horizontal line; from no symptom (minimal) to serious symptom (maximum).
Change from baseline stool consistency at eight weeksbaseline and eight weeksStool consistency by Bristol Stool Chart (type1-7)
Change from baseline Satiety evaluation at eight weeksbaseline and eight weeksSatiety response will be measured using subjective perceptions of hunger, fullness, satisfaction, and prospective food intake evaluated by previously validated visual analogue scales (VAS) (on a 90mm horizontal line; from no sensation of satiety (minimal) to strong sensation of satiety (maximum).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026